Enfortumab Vedotin in urothelial cancer

The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based chemotherapy has changed significantly over the last 5 years with the recent approvals of the immune checkpoint inhibitors (ICIs), fibroblast growth factor receptor (FGFR) inhibitors and most recently Enf...

Descripción completa

Detalles Bibliográficos
Autores principales: Alt, Marie, Stecca, Carlos, Tobin, Swanee, Jiang, Di Maria, Sridhar, Srikala S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780177/
https://www.ncbi.nlm.nih.gov/pubmed/33447264
http://dx.doi.org/10.1177/1756287220980192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780177/
https://www.ncbi.nlm.nih.gov/pubmed/33447264
http://dx.doi.org/10.1177/1756287220980192

Ejemplares similares